MedTrace Logo

HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients

NCT02273791 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2018-10-29

No results posted yet for this study

Summary

Evaluation of endometrial preparation using either hormonal therapy or ovarian stimulation prior to frozen-thawed embryo transfer (FET) in patients with polycystic ovarian syndrome (PCOS)

Conditions

Interventions

DRUG

Estradiol valerate

Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.

DRUG

Sequential Clomiphene citrate and Gonadotropin

Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Principal Investigators

  • Mohamed S Abdelhafez, Dr · Mansoura University

  • Mohamed I Eid, Dr · Mansoura University

  • Mahmoud M Abdelrazik, Dr · Mansoura University

  • Maher S Elsegaey, Dr · Mansoura University

  • Ahmed Badawy, Prof · Mansoura University

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-03-31
Completion
2016-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02273791 on ClinicalTrials.gov